This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk03: Good morning, and welcome to the Anovex Life Sciences Fiscal 2024 Second Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and during this session, if you would like to ask a question, use the Q&A box or raise your hand. Please note, this conference is being recorded. The call will be available for replay on Anovex's website at www.anovex.com. With us today is Dr. Christopher Misling, President and Chief Executive Officer, and Sandra Burnish, Principal Financial Officer. Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SCC. This includes without limitation the company's forms 10K and 10Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include without limitation risks inherent in the development and or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. And with that, I would like to turn the call over to Dr. Mislan.
spk01: Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update. We are encouraged by the very recently issued FDA guidance for early Alzheimer's disease, which states that one cognitive measures alone, like others COG, could be a sufficient primary endpoint for early Alzheimer's disease. We appreciate this new guidance and believe this opens another possible pathway for us to move forward in parallel to the initiated process of market authorization application to the European Medicine Agency, EMA, for Blacarmazine for the treatment of Alzheimer's disease. which are already underway. Full data from the Blacarmazine study in Alzheimer's disease phase 2B-3 placebo-controlled clinical trial will be published in an upcoming peer-reviewed journal. As well, analysis of RNA sequencing of the trial is underway, and interim data is expected by mid-2024. Concurrently, the AttentionAD open label extension trial is ongoing, and we expect to be able to share interim data in the second half of 2024. In RAD syndrome, continued positive real-world evidence feedback from RAD syndrome patients and caregivers participating in the ongoing open-label extension trial and compassionate use program for patients who participated in the excellence trial encourages us to continue our partnership with the RAD syndrome community and to proceed with a phase 3 12-week efficacy study. An educational presentation will be provided at the 2024 IRSF Rett Syndrome Scientific Meeting taking place this year, June 18 to 19, 2024. Regarding Parkinson's disease, initiation of a ANAVEX 273 Phase IIb-III six-month trial is expected in the second half of 2024. In Fragile X, new specific translatable and objective biomarker data generated with Anavex 273 supporting the initiation of the potentially pivotal Anavex 273 phase two slash three clinical trial will be presented at the 19th National Fragile X Foundation Conference taking place in July 25th to July 28th, 2024. Related to a new rare disease, we are also in preparation to initiate a potentially pivotal Anavax 273 phase two slash three trial. With respect to Anavax 371, we are quite pleased to provide an update that the placebo controlled phase two clinical trial of Anavax 371 for the treatment of schizophrenia. The study is well underway with the first cohort of schizophrenia patients being fully enrolled. We are also expecting further peer-reviewed clinical publications involving both Anavex 273 and Anavex 371. And now I would like to direct the call to Sandra Boenisch, Principal Financial Officer of Anavex, for a financial summary of the recently reported quarter.
spk00: Thank you, Christopher, and good morning to everyone. I'm pleased to share with you today our second quarter financial results for the 2024 fiscal year. Our cash position at March 31st was $139.4 million. During the quarter, we utilized cash and cash equivalents of $11.7 million in operating activities after taking into account changes in non-cash working capital accounts. At our current cash utilization rate, we believe we have cash runaway approximately four years. During our most recent quarter, our general administrative expenses were 2.8 million as compared to 2.6 million in the immediately preceding first quarter. Our research and development expenses for the quarter were 9.7 million as compared to 8.7 million for the immediately preceding first quarter. And lastly, we are reporting a net loss of 10.5 million for the quarter or 13 cents per share. And thank you. Now back to you, Christopher.
spk01: Thank you, Sandra. This is an exciting time for the company, and we are very excited to be entering a new phase of the company's history with our biomarker-driven precision medicine programs. I would now like to turn the call back to Clint for Q&A.
spk03: Thank you, Christopher. We'll now begin the Q&A session. If you have a question, raise your hand or put it in the Q&A box. And it looks like our first call is coming from Shumit from Jones Research. You should be live, Shumit.
spk05: Yeah. Congratulations on all the progress. And a few questions on the FDA guidance. oftentimes a bit qualitative and trying to understand, read through the line when they're saying strong biomarker and strong statistical data to support the clinical outcome on the cognition front. How do you really interpret that when you're looking at amyloid 42 over 40 ratio, the error bars when you compare with the company is just because of the cohort size is a little larger. How many patients was there and do you see these to be considered strong or IFD would ask for a larger trial. I was curious about your thoughts.
spk01: So the key background is that for the biomarker of Abeta changes in placebo versus active arm, we have to be reminded that the mechanism of our drug is not an antibody removing Abeta drug. but it's an orally available, once daily, easy to administer and scalable drug and has for that a lot of convenience features which the antibodies don't have in addition to the fact that they are having challenges with the black box warning which they have been given. So there's also a challenge from safety and repeated safety measures on MRI are required. Regarding the biomarker data of the A-beta, we were intrigued, but on the other hand, not surprised that we saw a reduction of A-beta in the brain measured by the plasma A-beta 4240 ratio, which is the analogy of measuring a PET A-beta level in the brain. which is intuitively easier to understand because you are showing a decline in the brain. But the Abeta 40 to 40 ratio, which again is representative of this fact of reduction of Abeta in the brain, is then measured in the plasma and shows as an increase of this ratio, favorably showing a decrease in the brain. So if the ratio goes up, that means Abeta in the brain goes down. So since we don't target EBETA directly with our drug, but have a more upstream mechanism of action, again, we were intrigued and surprised to see in all patients, you know, there was no sub analysis in this analysis of the EBETA ratio showing a significant decline. So now it's a question of dialogue with the agency, how this will be interpretable as a biomarker. But I'd like to also point out we have a second strong biomarker, which probably even is stronger, specifically from a p-value perspective, which is the changes in the atrophy of the brain. So in the pathology of the Alzheimer disease, there is a very well understood feature of shrinking of the brain over time. And this is intuitive. If the brain is shrinking, is less active, it cannot have as good memory or activities of execution and function as the brain was not shrinking. And we noticed in our trial a significant stopping of the shrinking of the brain with Anavex 273 lacarmazine in the active arm compared to placebo. So the placebo arm continues to shrink the brain in the patients while they are on placebo. which is standard of care, by the way, it's not placebo itself, it's including donepezil, memantine. So all the data is always on top of standard of care, which is today includes approved drugs. And however, the active arm on black carmesin or Navex 273 shows a significant separation from the placebo by not shrinking the brain any further or delaying the shrinking of the brain in many regions of the brain. And this exact data will be a part of the publication which we're expecting. So I think once this data comes out, I think then we can rediscuss the impact of that biomarker in combination with the Abeta biomarker. And again, with the Abeta biomarker, I'd like to remind again, we did not target with our drug directly Abeta. So it must be a downstream effect of the upstream feature of the sigma-1 receptor, showing also the impact on the entire population in our trial.
spk05: These are truly encouraging data. You have quite a few catalysts coming up in the next probably three months. I'm trying to understand what would be the strategy when you go to FDA? Would you wait for the open-label extension on trial data to come out along with the publication and completion of the European filing and then approach to FDA with the totality of data with biomarker and the long-term? Or would you meet with FDA before the long-term extension on trial data?
spk01: Yeah, so we really want to have the best impact, I would say. And you don't have a second chance for first impression, as they say. And certainly having data of the open label study, which is 96 weeks, probably would be favorable. However, we have not decided how to proceed on the timing exactly, but definitely this year. But also we can do, since it's an open label, interim cuts. So there's a way to expedite the analysis of the open label study.
spk05: That is truly helpful. Last question on if you can provide any guidance on the timeline around completion of the European filings.
spk01: Yeah, so we definitely want to expedite this and the teams are working really overtime to put together the modules, which are many pages, a significant package. We talk about a lot of documents and they all have to be completely ready. Usually this takes time and other companies going through the same process need the same time. So we are not in a different situation like that. But we said we want to submit this year and we are well on track to do that. So we will provide updated timing when we get closer to the filing time. But we are very good on time with that. So stay tuned.
spk05: Thank you. Congratulations on all the progress.
spk01: Thank you.
spk03: Our next call is coming from Ram at HC Wainwright. Ram, you should be live.
spk04: Can you hear me?
spk03: Yeah, perfect. Thank you.
spk04: Okay. With respect to the regulatory process with the European authorities, can you give us a sense of A, when you expect the MAA filing to be completed, and B, how you anticipate the process to evolve with respect to the CHMP review how and when they are likely to become involved in the review of the application, and what you understand to be the principal criteria they are going to use to evaluate the suitability of Blarc-Amacene for approval in the European Union. Thank you.
spk01: So we stated that just a minute ago that we are filing as soon as possible, definitely this year. And the team is really working overtime to put together the package, which has to be done in one submission. There's also interactions taking place with the EMA to be aligned on the technicalities. So that precedes these submission. We also are, sorry, what was the second question?
spk04: The involvement of the CHMP, that review committee that typically looks at drug candidates that are submitted to the EMA for approval and renders a positive or a negative opinion prior to an approval decision being taken. Just wanted to know, when you expect the CHMP to get involved in the review of the Blar-Chamisine MAA and what criteria you expect them to use to determine what their opinion should be.
spk01: Right. Thank you for reminding. So the procedure of the submission involves a review of the package before it gets submitted. And it's a very healthy procedure because it allows exactly this intelligence to feedback to be received. So we expect this to take place. To give you a sense of the level of interest, we noted before that the reason we submitted to the AMA was not because we thought it would be a good idea, but because we shared the majority of the data with the AMA beforehand and asked for their feedback. input and their feedback and their response was unambiguous to request to immediately file a submission. So we of course hope that this initial feedback will continue to be the case down the road and right now we have no belief why it wouldn't, but that is of course up to the review. So we are coming in here, not that we push, but we were pulled into the submission, given probably the unmet need in Europe and also the fact that the European Union has not MRI or PET centers in all places in the countries of the European Union. like in certain countries, for example, like Hungary or Poland or Romania, there are not enough MRI centers, which would probably be needed for a antibody given its safety profile. So that's the best we can say at this point.
spk04: And with respect to 371, just wanted to A, get a sense of how you expect to monitor the efficacy profile of this compound in schizophrenia if you regard, for example, certain domains of the Pan-SS to be the most appropriate efficacy measures, as well as the extent to which you expect 371 to be differentiated from existing anti-schizophrenic medications and what you expect the principal areas of differentiation to be. For example, Is it safety and tolerability more so than the efficacy? Or do you expect on both the safety as well as the efficacy fronts, this drug candidate to demonstrate a differentiated profile versus currently marketed, for example, atypical antipsychotic medications?
spk01: Yeah, I think it's exactly as you stated. It could be really both. And if you look at the landscape of drug approvals, you want to always be better than what is out there on the market. So if you're able to show that the safety has a better feature, a better profile, and also translate into stronger, more meaningful efficacy both on the positive as well as the negative domains of schizophrenia, then this would be extremely valuable and helpful. We also want to point out in this study, we are focusing on EG-ERP as a considered surrogate biomarker of schizophrenia. So we are excited about finding out how the drug interacts in that regard. And it's a very elegant non-invasive methodology to identify that. But we also have included the standard PAN score in addition to this EGERP. So we might learn something about the effect of our drug in the study in those regard, which would then allow us to decide how to proceed with this drug in schizophrenia.
spk04: And then the last question is sort of a combination of a strategic and financial query. Let's say hypothetically that the EMA agrees that Blarkamacine is approvable for treatment of Alzheimer's disease in the European Union. At that juncture, strategically, what do you expect your preferred strategy to be in terms of whether or not you elect to undertake independent self-commercialization activities in Europe, or whether you at that point would look to identify a partner? And does your cash burn guidance of Runway for the next four years take into account any pre-launch activity-related expenses related to Blarkamacine for treatment of Alzheimer's disease in Europe? Or are you assuming that if you get an MAA approval that you will look to identify a partner with which to launch the drug in Europe? Thank you.
spk01: Thank you for the question. So what we try to decide when it comes to that point is what creates most value for shareholders. So if the most value is created by finding a partner and who has the expertise and the bandwidth and the strength of executing and maximizing sales of the drug, Blaccharmazine for Alzheimer's, with giving us the appropriate incentive to do so with the upfront payment, with milestone payments and royalties, that would be probably the choice. If, however, it is not the case, then there are certain combinations of such features where we could also consider a split ability to market the drug, which could also actually be beneficial for the company and shareholders because we might retain more upside down the road. So this is really a decision made at the point in time when we are there. to maximum shoulder value. On the other point, you asked about the cash utilization rate. Right now, we are not including any marketing expenses and it's also not necessary because if it comes to a approval, you would have the ability to raise funds, non-diluted fund with that funding and financing and these sort of, which would not dilute current shareholders. So you would not need to have that money in equity available if you would come to the point that you need to pay expenses for marketing entry for that reason. So we would be in a position to leverage the balance sheet without diluting existing shareholders.
spk04: Thank you for all the clarity and congrats again on all the progress.
spk01: Thank you.
spk03: Thank you, Ram. Next question comes from Tom Bishop at BI Research. Tom, you should be live. I think you're muted, Tom.
spk02: Okay.
spk03: Perfect.
spk02: Can you hear me?
spk03: Yeah, you're good. Thank you.
spk02: Okay. I wasn't clear about this comment about the first cohort of schizophrenia being fully enrolled. And is this a 30 day trial? So would data presumably be forthcoming? You know, in H2, at least?
spk01: So we have to finish the trial. So it consists of several cohorts and several parts. So this was the first cohort in first part. And again, I want to point out this is a testament of the execution of the team, which has done this so quickly. And again, we are ahead of time because we We are anticipating starting the trial actually in this quarter and we ended up starting the trial in the previous quarter and now already have enrolled the first cohort. So it's very encouraging. I would leave the analysis and when the study is finished, when we get closer to that point to announce that. But we are very encouraged so far about the speed and the process of the study.
spk02: Are these different cohorts, what are they targeting? And how long does the trial last in terms of dosing?
spk01: So there are two cohorts in two parts. The first part is just identifying the doses of what is the best dose for the schizophrenia patients. So it's an ascending dose escalation part. And the second part is then at the optimal dose, if you like, a longer study of almost 30 days. So that is the second part. So we are right now in the first part.
spk02: Okay. And it's good to hear about the phase three RET trial. What can you tell us about the timing and the number of patients? And I guess it's going to be 50-50 this time with placebo. Can you tell us more about the trial?
spk01: Right. So we really think that with Rett syndrome, we have really a good chance of what we refer to learn our lessons from the previous trial, where we really were only impacted by a very high placebo effect. And that was contributed among others, as you pointed out, to the two-to-one randomization, which gave the sense of a participating family to think that two-to-one means that two chances are higher to be on active arm and randomizing only a small portion, one-third, for placebo. So 60 patients ended up in the active arm and 30 in the placebo. But because of that, people thought or had the impression or certainly the aspiration to have a higher chance of being in the active arm. And that leads for those who are on placebo and have completely blinded, so don't know if they get the placebo or the active arm, to suspect or hope that they are in the active arm psychologically. So that's what is this bias most likely. So to avoid this, we would have a 50-50 randomization one-to-one so that there is no anticipated ability to expect that to be in the active arm. and triggering a placebo effect in the placebo arm. So that would be one thing. The other part is there are also features to reduce placebo response by features of the trial, which are specific to technicalities. And then we also would do a larger study. It turned out that indeed the measurements are volatile. and only a few participants in the placebo arm could basically cause noise of the signal to be not significant. And that's what we observed. So there was a very good trend and directional improvement, but we have to now make sure that the signal is strong enough to be significant. And that's the ability to do that. And the timing is, We will provide update when we get closer, but the community is receptive to this. We are engaging with the community as we speak. And also we mentioned that we are presenting at the conference in June in Colorado, as a matter of fact, to connect with the community about the next steps of this trial.
spk02: And you don't quite yet know the number in the trial, which would affect how long it takes to get it. to go on.
spk01: So the good news is that it's a relatively short trial. It's 12 weeks, so it's not too long. It can be done relatively timely because the matter of fact is it's not a long trial to begin with. And if there is, again, ability to scale this up and there's strong interest in an alternative marketed drug to Rett syndrome patients, this could help actually and accelerate this trial to start and to kick off. Again, we will provide update as we know more.
spk02: Okay, can you remind us of the Fragile X data to date? Is it just phase one kind of safety data and food data, or do I forget kind of some trial results we've gotten that you're considering moving to phase 2b3 trial?
spk01: Which indication? Sorry, I missed that.
spk02: Fragile X.
spk01: Yeah. So this is very intriguing data. It's a biomarker which is measurable both in patients, in humans, as well as in animals. And it's correlating very clearly, it has been published, to the pathology of fragile X or to showing a reduction of the pathology of fragile X. And this will be presented for the first time at the conference in July. And we're very excited about it because it strengthens the, first of all, the evidence that Fragile X is an extremely good indication for blood carmesin for Anavex 273. But also it would give us in a clinical trial a biomarker. which is so important in CNS, which is hard to find biomarkers of a pathology. So these are the two reasons why we're very excited about this presentation coming up.
spk02: So you could move into a potentially pivotal phase 2b3 trial just based on your biomarker data to date, is it?
spk01: Yeah, so that biomarker data we presented will also, we also, we have to also appreciate that there are physicians, patients, advocacy group who want to learn why would you, you know, why won't you be part of a trial? And this information would give somebody that information to say, to be excited about being part of a trial because of the fact that it would define the chances of being beneficial to a fragile X patient in real world. And that's what this biomarker data would be to get the excitement in the community to also then have a smooth enrollment and trial execution, which is important.
spk02: Finally, I just wanted to ask, I worry about, I never thought we'd see the stock under five again. let alone four. And I'm wondering if this could be concerned about the delay in the peer reviewed article that we've been anticipating for so long and possibly even the lack of any insider buying. I mean, is there something preventing legally the company from doing insider buying? And if not, I would highly encourage it to show some faith here.
spk01: Yeah, I appreciate the feedback. We are, of course, not happy about it either. But we have to also be aware that the whole market is in challenging positions. But the fortunate thing for us is that we have really enough cash without any debt. We have a very good team which can execute. We also hired additional team members. And we're expanding in our execution of trials, which we pointed out also today. And we are really excited and moving forward. So that's the part we can do, and that's what we will do. So it would be futile to comment on the stock market.
spk02: I mean, is there any chance of some insider buying? Is there some? The lawyer is telling you you can't do it.
spk01: But every director is, insider has the chance to buy. When we have a window, we have to check if we have a window. If we do have a window, this is a choice for every board member or insider to do. Thank you.
spk02: I was just wondering if the window is now closed and that's why we're not seeing.
spk01: It's right now closed, but it could open. So we will see.
spk02: All right. Thank you.
spk01: Thank you.
spk03: Looks like that's all the questions today, Dr. Mislink.
spk01: Thank you. And in closing, we remain committed to the development of our programs within neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, which could further expand our portfolio of transformative investigational therapies, utilizing our differentiated precision medicine platform to deliver easy access and scalable treatment options for brain disorders. We continue to focus on execution and commercial readiness as we advance our therapeutic pipeline to potentially improve patient lives living with these devastating conditions. Thank you very much.
spk03: Great. Thank you, ladies and gentlemen. That concludes today's conference call. We appreciate your participation. You're now welcome to disconnect.
Disclaimer